Novartis news from FierceHealthcare
NewsSPOTLIGHT: Pharmas focusing on pet psych meds
Did you ever think your dog could suffer from dementia, OCD or an anxiety disorder? Apparently, pharmaceutical giants like Pfizer, Eli Lilly and Novartis do. The drugmakers are dishing out human Read more...
ALSO NOTED: FDA sending fewer warning letters;IL law would limit what hospitals can charge uninsured patients; and much more...
> It looks like the FDA is sending out a lot fewer warning letters to potential violators of late. Officials say they're just changing emphasis, but critics suggest that th agency is slacking off. Read more...
ALSO NOTED: Wireless "white spaces" could disrupt care; MA hopes "medical homes" catch on; and much more...
> With telecommunications industry pressure mounting to put them to use, technology vendors and engineering groups are fighting what they say is a critical battle to protect so-called "white Read more...
ALSO NOTED: FDA may require side-effects hotline number in DTC ads; Many uninsured could be eligible for gov't insurance; and m
> An FDA panel is considering whether it should require direct-to-consumer advertisers to include a side-effects hotline in every commercial. Read more...
ALSO NOTED: FDA investigates Roche, Novartis transplant drugs; Maryland hospital fined for radiation errors; and much more...
> The FDA has started to investigate whether Roche's CellCept and Novartis' Myfortic, similar drugs used in transplants to prevent organ rejection, cause an often-fatal neurological disease. Read more...
| Press ReleasesUniversity Teams Tap Mobile Phones and Social Networks to Fight Non-communicable DiseasesUniversity of California, Berkeley and ESADE Business School-Universidad Ramon Llull Target Diabetes to win IBM and Novartis NCD ChallengeARMONK, N.Y., Feb. 9, 2012 /PRNewswire/ -- New solutions Read more >> First U.S. cell-based flu vaccine plant set for dedicationFacility’s ability to produce cell-based pandemic flu vaccine marks historic change WASHINGTON--(BUSINESS WIRE)-- The first U.S. facility to use a faster and more flexible technology to make Read more >> MyoPowers Closes Series B Investment of CHF 16 MillionTruffle Capital Leads Round, Joining Novartis Venture Funds and other Series A Investors to bring Artificial Sphincter Technology to Market LAUSANNE, Switzerland--(BUSINESS WIRE)-- MyoPowers Medical Read more >> |
